U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907875) titled 'A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy' on March 26.
Brief Summary: The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are:
How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working?
Participants will receive a single dose of EPI-321 through a vein while being closely watch...